BioAdvance β Full Portfolio
60 tracked investments Β· listed companies and verified rows first
Co-investorsFrazier Life Sciences
BiotechNew York, US
Sergio Traversa(Executive Officer, Director)Eliseo O. Salinas(President and Chief Scientific Officer)Douglas Beck(Chief Financial Officer)Charles Casamento(Director)Paul Kelly(Director)Maged Shenouda(Director)
RiboNova is a biopharmaceutical company developing small molecule drugs and precision medicines targeting transfer RNA for the treatment of mitochondrial disease.
BiotechDeep TechMedical DevicesWynnewood, US
Co-investorsMilitia Hill Ventures
Accelerated Biosciences commercializes human trophoblast stem cells (hTSC) and derived platforms for therapeutic development, serving pharmaceutical and biotech partners seeking accelerated pathways to clinical products.
BiotechHealthtechMedical Devices
Nurse retention platform designed to identify risk up to 12 months in advance.
Co-investorsOUP (Osage University Partners)Pfizer Venture Investments
Bainbridge Health provides software solutions for hospital pharmacy operations, including infusion safety analytics, IV formulation management, and drug library development.
Data & InfrastructureDigital HealthEnterprise SoftwareHealthtechMedical DevicesPhiladelphia, US
Sam Wilson(Executive Officer)Joseph Kaupp(Executive Officer, Director)Sean O'Neill(Executive Officer, Director)
BoardAmy Gallagher(Director)Shahram Hejazi(Director)Thomas Lynch(Director)
Co-investorsChestnut Street Ventures
BiotechHummelstown, US
Stephen C. Rocamboli(Executive Officer, Director)Rifat Pamukcu(Director)Robert Towarnicki(Executive Officer, Director)Roger Sawhney(Director)
BoardTim Van Treuren(Director)John Fucci(Director)in
Co-investorsLife Sciences Greenhouse InvestmentsBios Partners
Co-investorsOsage Venture Partners
HealthtechNew York, US
Melissa P. Manice(Executive Officer, Director)Daniel Weinstein(Executive Officer, Director)
BoardSteve Agular(Director)Sean Kearney(Director)
Concarlo Therapeutics develops cancer therapeutics that target CDK4/6-driven cell proliferation and CDK2-driven resistance, focusing on improving outcomes for cancer patients through novel approaches in p27 biology.
BiotechBrooklyn, US
Stacy Blain(Founder and CEO)LisaMarie Casey(President and Manager)
Co-investorsCreative Destruction Lab (CDL)Raptor Group
Eliksa Therapeutics develops innovative treatments for rare diseases with unmet medical needs.
BiotechDigital HealthMedical Devices
Co-investorsMilitia Hill VenturesBen Franklin Technology Partners
ENB Therapeutics develops small molecules targeting the endothelin B receptor (ETBR) in the tumor microenvironment to treat drug-resistant cancers by restoring immune cell infiltration and promoting tertiary lymphoid organ formation.
BiotechHealthtechNew York, US
Sumayah Jamal(President, Co-founder & Chief Scientific Officer)inRobert Schneider(Co-founder & Chair of Scientific Advisory Board)Sandy Harm(Chief Operating Officer)Fumitaka Mori(Director)Albert Sokol(Executive Officer)
BoardBarbara Schilberg(Director)
Co-investorsRemiges Ventures, Inc.
Hanimune Therapeutics develops therapeutics for food allergy prevention and tolerance support for pediatric and adult patients, drawing on immunological science and food protein research.
BiotechFoodTechHealthtechMedical Devices
Co-investorsRobin Hood Ventures
King Of Prussia, US
William Conlan(Executive Officer, Director)Mark McAdoo(Executive Officer, Director)
BoardDavid Tamburri(Director)Mike Kane(Director)
BiotechNew York, US
Nader Halim(Executive Officer, Director)Althea Stillman(Executive Officer, Director)
BoardJonathan Leff(Director)David Greenwald(Director)in
Co-investorsDeerfield Management Company
BiotechCranbury, US
Bo Liang(Executive Officer, Director)Houman Hemmati(Executive Officer, Director)Wei Wang(Executive Officer, Director)John J Baldwin(Director)Tao Du(Director)
BoardQi Zhu(Director)
KaloCyte develops ErythroMer, a dried, shelf-stable artificial red blood cell for use in emergency and trauma care when stored blood is unavailable or in short supply.
BiotechDeep TechHealthtechMedical DevicesBaltimore, US
Allan Doctor(Co-Founder & CSO)inDipanjan Pan(Co-Founder, Chief Technical Officer)inPhilip Spinella(Co-Founder, Chief Medical Officer)inDaniel Getman(Director)Gregory Lanza(Director)
Co-investorsBioGenerator VenturesMaryland TEDCONYBC VenturesOld Line Capital PartnersTEDCO
Keriton offers a software platform for neonatal and pediatric hospital settings that supports safe infant feeding practices, milk management (donor human milk, formula, and parental human milk), and family engagement through features like secure photo sharing, e-journaling, and clinician messaging.
BiotechDigital HealthHealthtechSaaSPhiladelphia, US
Vidur Shailendra Bhatnagar(Manager)
Co-investorsBroad Street AngelsDorm Room37 Angels
Gene therapy company; recently appointed Bethany Mancilla as Chief Business Officer.
Loudmark is a marketing and design agency that provides advertising, branding, graphic design, web development, event production, and packaging services to clients.
AdTechMarketing TechPeachtree City, US
Co-investorsFitz Gate Ventures
BiotechPhiladelphia, US
Shariff S. Bayoumy(Executive Officer)Brett A. Tounge(Executive Officer, Director)Lawrence C. Kuo(Executive Officer)Michael Serrano-Wu(Director)
BoardBarbara Schilberg(Director)
Melior Discovery provides in vivo pharmacology services and phenotypic screening platforms for pharmaceutical and biopharmaceutical companies to evaluate candidate therapeutics in animal disease models.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Andrew Reaume(President and CEO, Co-Founder)Andrew Reaume, PhD, MBA(President and CEO, Co-Founder)
BiotechSpring House, US
Rifat Pamukcu(Executive Officer, Director)
BoardHarry Arader(Director)
BiotechDoylestown, US
Osvaldo Flores(Executive Officer, Director)Daniel E. Geffken(Executive Officer)George Hartman(Executive Officer)Gregory Korbel(Executive Officer)
BoardTim Shannon(Director)Scott Rocklage(Director)
Co-investorsCanaan Partners5AM VenturesVersant Ventures
Co-investorsCota Capital
BiotechWayne, US
Roy Levitt(Executive Officer, Director)Stephen Tullman(Executive Officer, Director)Paul Barone(Executive Officer, Director)Brian Lortie(Executive Officer, Director)Douglas Gessl(Executive Officer)
BiotechBryn Mawr, US
Martin D. Phillips(Executive Officer, Director)Nicholas W. Lukacs(Director)Frank Marcoux(Director)Alan E. Casnoff(Director)
Ossianix develops TXP1, a brain-selective shuttle based on a deimmunised VNAR antibody scaffold that targets TfR1 to carry therapeutic payloads across the blood-brain barrier.
BiotechDeep TechHealthtech
Frank S Walsh(CEO (Founder))J Lynn Rutkowski(CSO (Founder))Steve Moore(COO)Pawel Stocki(VP Research)
Phrase Health provides analytics tools for health systems to reduce unwarranted clinical variation within the electronic health record (EHR), aiming to lower costs and improve patient outcomes.
Digital HealthHealthtechSaaSPhiladelphia, US
Marc Tobias, MD, FAMIA(Founder)inMichael Zeidlhack(Executive Officer, Director)Marc Tobias(Founder)inNaveen Muthu(Director)in
Co-investorsLionBird
New York, US
Emanuele Musini(CEO and Director)James Wyman(CFO and Director)
BoardYogendra Jain(Director)
Co-investorsHackensack Meridian Health Bear's Den
BiotechGreenwhich, US
Wendy DiCicco(Ms. DiCicco is the Secretary and Treasurer of the Issuer.)Arthur Feldman(Director)Magdalene Cook(Executive Officer, Director)Campbell Murray(Director)Edward J. Benz, Jr.(Director)Thomas Needham(Director)
Co-investorsElysia Capital
Tolerance is a compliance platform that runs continuous automated checks against the NIST 800-171 standard and collects assessor-ready evidence for teams handling Controlled Unclassified Information (CUI).
CybersecurityGovTechSaaS
Co-investorsDorm RoomAmadeus Capital PartnersBen Franklin Technology PartnersColumbus Venture PartnersCriteria Bio VenturesEast Innovate+4 more
BiotechPhiladelphia, US
Francisco Leon(Executive Officer, Director)Philip Ball(Executive Officer, Director)Justin Vogel(Executive Officer, Director)
BoardDamia Tormo Carulla(Director)Pablo Cironi(Director)inRobert Goldstein(Director)
Co-investorsCriteria Bio VenturesBen Franklin Technology PartnersColumbus Venture Partners
Developing ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor combination for complicated urinary tract infections.
Malvern, US
Co-investorsAMR Action FundForesite Capital
Vesteck develops medical device technology in the cardiovascular/endovascular space.
HealthtechMedical DevicesWest Chester, US
JOSEPH W. RAFFERTY(Executive Officer, Director, Promoter)Rafferty Joseph(Executive Officer, Director)Edward Wulfman(Executive Officer)John Edoga(Director)JOHN DIEDERICH(Director)THIERRY RICHARD(Director)
Co-investorsNew World AngelsOcean Azul PartnersRobin Hood Ventures
Vittoria develops immunotherapies, specifically CAR T-cell therapies, to treat difficult-to-treat diseases including cancers beyond B-cell types.
BiotechDeep TechMedical Devices
Co-investorsGlobal BioAccess FundAgent Capital
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.